Alimera Sciences (NASDAQ:ALIM) Coverage Initiated by Analysts at assumed coverage on shares of Alimera Sciences (NASDAQ:ALIMGet Rating) in a research note released on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on ALIM. Alliance Global Partners dropped their price objective on Alimera Sciences from $14.50 to $11.00 in a research note on Friday, February 25th. Zacks Investment Research lowered Alimera Sciences from a hold rating to a strong sell rating in a research note on Tuesday, March 1st. Finally, HC Wainwright dropped their price target on Alimera Sciences from $12.00 to $10.00 and set a buy rating for the company in a research note on Friday, February 25th.

Shares of NASDAQ ALIM opened at $6.02 on Monday. Alimera Sciences has a fifty-two week low of $3.94 and a fifty-two week high of $11.85. The stock has a fifty day moving average of $5.13 and a 200-day moving average of $4.92.

Alimera Sciences (NASDAQ:ALIMGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.21). The firm had revenue of $13.96 million during the quarter, compared to the consensus estimate of $14.00 million. During the same period in the previous year, the business posted ($0.18) EPS. As a group, equities research analysts predict that Alimera Sciences will post -1.89 earnings per share for the current year.

In related news, major shareholder Stanley Morgan sold 250,000 shares of the business’s stock in a transaction dated Tuesday, February 8th. The stock was sold at an average price of $4.55, for a total transaction of $1,137,500.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. 13.50% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of ALIM. Millennium Management LLC purchased a new position in shares of Alimera Sciences during the 4th quarter worth approximately $65,000. Ensign Peak Advisors Inc bought a new stake in shares of Alimera Sciences in the 3rd quarter worth approximately $81,000. Finally, Morgan Stanley boosted its position in shares of Alimera Sciences by 0.7% in the 2nd quarter. Morgan Stanley now owns 428,109 shares of the biopharmaceutical company’s stock worth $3,896,000 after purchasing an additional 2,797 shares in the last quarter. Hedge funds and other institutional investors own 28.17% of the company’s stock.

About Alimera Sciences (Get Rating)

Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.

Featured Articles

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.